The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways

Objective: This study aims to provide an up-to-date analysis of the current state of patient access to new drugs in South Korea, focusing on the effect of new review pathways for reimbursement.Methods: We analyzed patients’ access to new drugs, listing rate and lead time until listing from marketing authorization. New pathways were defined as ‘price negotiation waiver,’ ‘risk-sharing agreements,’ and ‘pharmacoeconomic evaluation...